Intravenous (IV) opioids are an important treatment option for millions of hospital patients, with over 45 million patients estimated to receive this type of analgesic each year.1 For surgeries where severe, prolonged, or deep/visceral pain is expected, IV opioids are considered an essential component of a patient’s pain management regimen. The number of these complex and painful procedures is increasing, representing a growing burden on hospital systems.2 However, drugs like IV morphine have limitations, including adverse effects such as nausea, vomiting, and respiratory depression, all of which can negatively impact a patient’s recovery.3,4,5
There remains a significant clinical need for an effective and well-tolerated IV analgesic, particularly for patients who are more susceptible to these dose-limiting adverse effects, such as those who are elderly, obese, or renally-impaired. Current hospital trends suggest that the number of these high-risk patients is growing.7,8
Trevena’s lead product candidate, oliceridine injection, is a first-in-class IV analgesic in development for the management of moderate to severe acute pain. Oliceridine is the first G protein-selective agonist and was designed to deliver an improved analgesic profile compared to IV morphine. It targets the mu-opioid receptor with an optimized mechanism of action (MOA) that preferentially engages the signaling pathway responsible for efficacy, with reduced activation of the signaling pathway responsible for adverse effects.
|Program||Molecular Target||Therapeutic Target||Current Phase||PC||PH1||PH2||PH3||NDA|
|Oliceridine||Mu receptor||Moderate-to-severe acute pain||NDA||Intravenous PC complete||PH1 complete||PH2 complete||PH3 complete||NDA in progress|